BACKGROUND: Women of childbearing age are commonly prescribed medications by primary care providers (PCPs) that may cause birth defects if used during pregnancy. METHODS: To identify what PCPs perceive as barriers to and potential facilitators of providing counseling to women of childbearing age when teratogenic medications are prescribed, we conducted eight focus groups with 48 PCPs recruited from four clinical settings in Pittsburgh, Pennsylvania. We explored PCPs' experiences counseling women about teratogenic medications. Each focus group was audio-recorded, transcribed, and coded using a grounded theory approach by three independent coders. RESULTS: PCPs feel responsible for counseling women when they prescribe medications that may cause birth defects, but note difficulties identifying clinically relevant sources of information on teratogenicity. Other barriers to providing counseling include limited visit times and lack of reimbursement for preconception or teratogenic risk counseling. PCPs find it challenging to identify patients who may become pregnant and who therefore need contraceptive and/or teratogenic risk counseling. PCPs expressed a desire for online resources that could be used when explaining medication risks to patients. PCPs feel that the development of patient information materials, electronic decision support tools, clinical care systems that routinely assess patients' pregnancy risk, and changes in the reimbursement structure may facilitate counseling patients about teratogenic risks. CONCLUSIONS: PCPs perceive themselves as playing an important role in providing their patients information on risk of medication-induced birth defects. To ensure safe prescription of teratogenic medications, PCPs suggest interventions at both the clinic and healthcare system levels.
BACKGROUND:Women of childbearing age are commonly prescribed medications by primary care providers (PCPs) that may cause birth defects if used during pregnancy. METHODS: To identify what PCPs perceive as barriers to and potential facilitators of providing counseling to women of childbearing age when teratogenic medications are prescribed, we conducted eight focus groups with 48 PCPs recruited from four clinical settings in Pittsburgh, Pennsylvania. We explored PCPs' experiences counseling women about teratogenic medications. Each focus group was audio-recorded, transcribed, and coded using a grounded theory approach by three independent coders. RESULTS: PCPs feel responsible for counseling women when they prescribe medications that may cause birth defects, but note difficulties identifying clinically relevant sources of information on teratogenicity. Other barriers to providing counseling include limited visit times and lack of reimbursement for preconception or teratogenic risk counseling. PCPs find it challenging to identify patients who may become pregnant and who therefore need contraceptive and/or teratogenic risk counseling. PCPs expressed a desire for online resources that could be used when explaining medication risks to patients. PCPs feel that the development of patient information materials, electronic decision support tools, clinical care systems that routinely assess patients' pregnancy risk, and changes in the reimbursement structure may facilitate counseling patients about teratogenic risks. CONCLUSIONS: PCPs perceive themselves as playing an important role in providing their patients information on risk of medication-induced birth defects. To ensure safe prescription of teratogenic medications, PCPs suggest interventions at both the clinic and healthcare system levels.
Authors: Susan E Andrade; Marsha A Raebel; Abraham N Morse; Robert L Davis; K Arnold Chan; Jonathan A Finkelstein; Kris K Fortman; Heather McPhillips; Douglas Roblin; David H Smith; Marianne Ulcickas Yood; Richard Platt; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2006-08 Impact factor: 2.890
Authors: Eleanor Bimla Schwarz; Debbie A Postlethwaite; Yun-Yi Hung; Mary Anne Armstrong Journal: Ann Intern Med Date: 2007-09-18 Impact factor: 25.391
Authors: Susan E Andrade; Marsha A Raebel; Jeffrey Brown; Kimberly Lane; James Livingston; Denise Boudreau; Sharon J Rolnick; Douglas Roblin; David H Smith; Gerald J Dal Pan; Pamela E Scott; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2008-03 Impact factor: 2.890
Authors: Susan E Andrade; Jerry H Gurwitz; Robert L Davis; K Arnold Chan; Jonathan A Finkelstein; Kris Fortman; Heather McPhillips; Marsha A Raebel; Douglas Roblin; David H Smith; Marianne Ulcickas Yood; Abraham N Morse; Richard Platt Journal: Am J Obstet Gynecol Date: 2004-08 Impact factor: 8.661
Authors: Rachael R Dirksen; Benjamin Shulman; Stephanie B Teal; Amy G Huebschmann Journal: J Womens Health (Larchmt) Date: 2014-04-25 Impact factor: 2.681
Authors: Sheila K Mody; Jennifer Wu; Marla Ornelas; Colleen Kernahan; Elizabeth Salas; Kelly Kao; Robert Felix; Christina Chambers Journal: Birth Defects Res A Clin Mol Teratol Date: 2015-06-23
Authors: Eleanor Bimla Schwarz; Sara M Parisi; Sanithia L Williams; Grant J Shevchik; Rachel Hess Journal: Ann Fam Med Date: 2012 Nov-Dec Impact factor: 5.166
Authors: Eleanor Bimla Schwarz; Sara M Parisi; Steven M Handler; Gideon Koren; Elan D Cohen; Grant J Shevchik; Gary S Fischer Journal: J Gen Intern Med Date: 2012-07 Impact factor: 5.128
Authors: Tiffany Behringer; Bruce L Rollman; Bea Herbeck-Belnap; Patricia R Houck; Sati Mazumdar; Eleanor Bimla Schwarz Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Molly M Lynch; Jacqueline B Amoozegar; Emily M McClure; Linda B Squiers; Cheryl S Broussard; Jennifer N Lind; Kara N Polen; Meghan T Frey; Suzanne M Gilboa; Janis Biermann Journal: Qual Health Res Date: 2017-10-03
Authors: Rex W Force; Gina A Keppel; Janelle Guirguis-Blake; Debra A Gould; Chris Vincent; Kavitha Chunchu; Robert M Monger; John T Holmes; Jacintha Cauffield; Laura-Mae Baldwin Journal: J Am Board Fam Med Date: 2012 Sep-Oct Impact factor: 2.657
Authors: Kristin Palmsten; Dani Bredesen; Meghan M JaKa; Pritika C Kumar; Jeanette Y Ziegenfuss; Elyse O Kharbanda Journal: Pharmacoepidemiol Drug Saf Date: 2020-12-22 Impact factor: 2.890